Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · lung-landscapes@6

SRR6013559

— · cohortMD2

7e60a363-62c9-5041-baf0-c4d99a516529

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
cohortMD2
subtype
cohortMD2

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • INTERFERON_ALPHA_RESPONSE+0.520
  • INTERFERON_GAMMA_RESPONSE+0.420
  • ALLOGRAFT_REJECTION+0.270
  • PI3K_AKT_MTOR_SIGNALING+0.230
  • IL6_JAK_STAT3_SIGNALING+0.220
  • MYOGENESIS+0.200
  • COMPLEMENT+0.190
  • XENOBIOTIC_METABOLISM+0.190
  • IL2_STAT5_SIGNALING+0.180
  • PEROXISOME+0.170

Top 10 suppressed

  • ANGIOGENESIS-0.340
  • MYC_TARGETS_V1-0.300
  • E2F_TARGETS-0.280
  • G2M_CHECKPOINT-0.270
  • MTORC1_SIGNALING-0.260
  • SPERMATOGENESIS-0.240
  • HYPOXIA-0.210
  • NOTCH_SIGNALING-0.210
  • CHOLESTEROL_HOMEOSTASIS-0.170
  • KRAS_SIGNALING_DN-0.160

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

6 twins match this tumor's tissue · 4 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR8526721
lung-landscapes@6
—cohortA10.774
2TCGA-78-7539-01A-11R-2066-07
lung-landscapes@6
—cohortA10.752
3MDT-AP-1175
medullo-epn-umap@date-based
MedMedulloblastoma0.749
4131532
medullo-epn-umap@date-based
EPNEPN Tumor0.743
5TCGA-QK-A652-01A-11R-A30B-07
head-neck@1
——0.723
6MDT-AP-1385
medullo-epn-umap@date-based
MedMedulloblastoma0.721
7TCGA-97-A4M6-01A-11R-A24X-07
lung-landscapes@6
—cohortA10.721
8X1c87996e.59e7.495f.8c4e.f578c7e10ba8
lung-landscapes@6
—cohortMD20.716
9SRR13780265
lung-landscapes@6
—cohortMD20.712
10SRR665670
brain-umap@2
GTEX—0.711

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 26 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
INTERFERON_ALPHA_RESPONSE0.520Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.420Idelalisib— uncovered
ALLOGRAFT_REJECTION0.270Idelalisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.230Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.220Inavolisib— uncovered
MYOGENESIS0.200Inavolisib— uncovered
COMPLEMENT0.190Inavolisib— uncovered
XENOBIOTIC_METABOLISM0.190Inavolisib— uncovered
IL2_STAT5_SIGNALING0.180Idelalisib— uncovered
PEROXISOME0.170Idelalisib— uncovered
KRAS_SIGNALING_UP0.150Inavolisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.150Inavolisib— uncovered
UV_RESPONSE_UP0.140Idelalisib— uncovered
APICAL_JUNCTION0.120Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.110Idelalisib— uncovered
ADIPOGENESIS0.100Inavolisib— uncovered
ESTROGEN_RESPONSE_EARLY0.090Inavolisib— uncovered
TGF_BETA_SIGNALING0.090Inavolisib— uncovered
BILE_ACID_METABOLISM0.080Inavolisib— uncovered
COAGULATION0.080Binimetinib— uncovered